In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

GSK shares have set a fresh low for the year, falling 49p to 1402p even though its core earnings figure of 49.7p a share beat ...

GSK is delivering consistent financial performance ... So with that, I'll now hand over to Luke and Deborah to talk you through our commercial performance. Thanks, Emma. Please turn to the ...